Showing 3341-3350 of 5773 results for "".
- Haag-Streit to Present Ophthalmic Skills Training Center Concept at ESCRS 2023https://modernod.com/news/haag-streit-to-present-ophthalmic-skills-training-center-concept-at-escrs-2023/2481783/Haag-Streit announced it is showcasing the 'Ophthalmic Skills Training Center (OSTC)' at this year's Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). At the core of the Ophthalmic Skills Training Center is the combination of
- Lupin Receives FDA Approval for Generic Bromday Equivalenthttps://modernod.com/news/lupin-receives-fda-approval-for-generic-ophthalmic-solution/2481778/India-based Lupin announced that it has received approval from the FDA for its abbreviated new drug application for bromfenac ophthalmic solution 0.09% for the treatment of postoperative inflammation and pain. The product is a generic equivalent of Bromday&
- Rayner Completes First Implantations of IOLs in Clinical Trials in China and the UShttps://modernod.com/news/rayner-achieves-milestone-implantations-in-clinical-trials-in-china-and-the-us/2481774/Rayner has announced the completion of the first implantations in two pivotal market access studies in the US and China. Rayner's RayOne EMV Toric IOL received investigational device exemption (IDE) approval from the FDA in June. The first study implantation took place at
- Myopia Profile Launches New Educational Websitehttps://modernod.com/news/myopia-profile-launches-new-educational-website/2481773/Myopia Profile announced the launch of its redesigned website,
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- ESCRS Launches New Clinical Research Award Call Focusing on Presbyopic IOLs in Post-Refractive Cataract Patientshttps://modernod.com/news/escrs-launches-new-clinical-research-award-call-focusing-on-presbyopic-iols-in-post-refractive-cataract-patients/2481768/The European Society of Cataract & Refractive Surgeons (ESCRS) announced the opening of a call for applications for the 2023 Clinical Research Award. The ESCRS Clinical Research Awards (CRA) is an initiative by the ESCRS to support and encourage independent clinical research in the
- Haag-Streit to Host ‘Eyestar 900 Pearls of Cataract & Refractive Surgery with Swept-Source OCT’ Satellite Symposiumhttps://modernod.com/news/haag-streit-to-host-eyestar-900-pearls-of-cataract-refractive-surgery-with-swept-source-oct-satellite-symposium/2481767/Haag-Streit announced it will host the ‘Eyestar 900 Pearls of Cataract & Refractive Surgery with Swept-Source OCT’ Satellite Symposium at the 41st Congress of the ESCRS in September. Haag-Streit invites delegates to join its distinguished faculty for
- Laboratoires Théa Acquires ProQR Therapeutics' Sepofarsen and Ultevursenhttps://modernod.com/news/laboratoires-thea-acquires-proqr-therapeutics-sepofarsen-and-ultevursen/2481765/ProQR Therapeutics and Laboratoires Théa announced an agreement in which ProQR will divest its late stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5 million ($13.7 m
- Iveric Bio Receives FDA Approval for Izervay for Geographic Atrophyhttps://modernod.com/news/iveric-bio-receives-fda-approval-for-izervay-for-geographic-atrophy/2481764/Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), parent company Astellas Pharma announced Friday night. Izervay, a new complem
- Oculis’ OCS-01 Eye Drops Studied in LEOPARD Trial to Treat Cystoid Macular Edemahttps://modernod.com/news/oculis-ocs-01-eye-drops-studied-in-leopard-trial-to-treat-cystoid-macular-edema/2481763/Oculis announced that the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ high-concentration preservative-free topical Optireach formulation of dexamethasone, for the treatment of cystoid macular edema (CME).<